Bevacizumab BS IV infusion 400mg “Daiichi Sankyo” is a biosimilar of bevacizumab (genetical recombination), manufactured by Daiichi Sankyo. This injectable drug (YJ code: 4291450A2020) is supplied as 400mg in 16mL per bottle, used to treat various cancers including metastatic colorectal cancer, non-small cell lung cancer, and kidney cancer.
Bevacizumab BS IV infusion 400mg “Daiichi Sankyo”
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →